LUTATHERA® (lutetium (177Lu) oxodotreotide) Approved in Canada

LUTATHERA® (lutetium (177Lu) oxodotreotide) Approved in Canada

Bill Dickie, President and CEO of Advanced Accelerator Applications (AAA) Canada Inc., stated,

“As the first ever approved Peptide Receptor Radionuclide Therapy (PRRT) in Canada, Lutathera represents a significant innovation for the neuroendocrine tumor community. We are proud to work with the Federal and Provincial agencies to make this important treatment option accessible for all patients who need such therapy.

We believe nuclear medicine has the potential to offer many benefits to cancer patients and hope to bring further advances like Lutathera to Canada in the future. The approval of therapies like Lutathera help highlight the role of medical radiation technologists in patient care.”

No Comments

Post a Reply